Drugs / ACP-001
ACP-001
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01010425 | Nov 2009 → Feb 2010 | — | Ascendis Pharma A/S | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT01947907 | Jul 2013 → Jul 2015 | — | Ascendis Pharma A/S | Completed | No outcome recorded |
| Phase 2 | NCT01247675 | Nov 2010 → May 2011 | pituitary deficiency | Ascendis Pharma A/S | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2026-08-06 | Ascendis Pharma A/S | Results Ascendis Announces COACH Week 78 Results and Provides Update on Achondroplasia Programs and YUVIWEL® Uptake in the U.S. ascendispharma.com ↗
TransCon® CNP and TransCon hGH combination therapy Week 78 data from the Phase 2 COACH Trial showed durable, unprecedented increase in healthy, proportional growth |
| 2026-06-25 | Ascendis Pharma A/S | Results Ascendis to Showcase Advances in Treatment of Achondroplasia at ICCBH 2026 ascendispharma.com ↗
These follow-up data reinforce the unique benefits of TransCon CNP alone and in combination with TransCon hGH |
| 2026-04-08 | Ascendis Pharma A/S | Results New Data from Week 52 of the Ongoing COACH Trial Showed that TransCon® hGH Accelerated TransCon® CNP’s Benefits Beyond Linear Growth in Children with Achondroplasia ascendispharma.com ↗
Ascendis Pharma A/S (Nasdaq: ASND) today announced new data demonstrating TransCon hGH accelerated TransCon CNP’s benefits beyond linear growth with substantial improvements in arm span, spinal canal dimensions, and lower limb alignment. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-08-06 | Ascendis Pharma A/S | Ascendis Announces COACH Week 78 Results and Provides Update on Achondroplasia Programs and YUVIWEL® Uptake in the U.S. ascendispharma.com ↗ |
| 2026-06-25 | Ascendis Pharma A/S | Ascendis to Showcase Advances in Treatment of Achondroplasia at ICCBH 2026 ascendispharma.com ↗ |
| 2026-04-08 | Ascendis Pharma A/S | New Data from Week 52 of the Ongoing COACH Trial Showed that TransCon® hGH Accelerated TransCon® CNP’s Benefits Beyond Linear Growth in Children with Achondroplasia ascendispharma.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ACP-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01010425 ↗ |
| Known as | TransCon growth hormone | “TransCon growth hormone (GH) is a sustained-release inactive prodrug consisting of unmodified GH transiently bound to an inert carrier molecule designed to release fully active...” PMID 29273485 ↗ Dec 2017 |
| Known as | TransCon hGH | “ACP-001 (TransCon hGH)” NCT01247675 ↗ |
| Known as | TransCon PEG hGH | “ACP-001 (TransCon PEG hGH)” NCT01010425 ↗ |
| Modality | Protein / enzyme biologic | “long-acting recombinant sustained-release human GH prodrug” PMID 28201598 ↗ May 2017 |
| Route | Subcutaneous | “Once weekly subcutaneous injection of ACP-001” NCT01247675 ↗ |